quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·37d
PRRelease
Incyte Corp. logo

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

INCY· Incyte Corp.
Health Care
Original source

Companies

  • INCY
    Incyte Corp.
    Health Care

Recent analyst ratings

  • Mar 16UpdateJefferies$94.00
  • Feb 5UpdateH.C. Wainwright$135.00
  • Jan 20UpdateWells Fargo$107.00
  • Dec 8UpdateMizuho$121.00
  • Nov 3UpdateGuggenheim$125.00
  • Oct 8UpdateOppenheimer-

Related

  • PR21h
    MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
  • INSIDER2d
    SEC Form 4 filed by Cagnoni Pablo J
  • INSIDER6d
    SEC Form 4 filed by Meury William
  • INSIDER6d
    SEC Form 4 filed by Cagnoni Pablo J
  • INSIDER6d
    SEC Form 4 filed by Stein Steven H
  • PR14d
    Incyte to Report First Quarter Financial Results
  • PR16d
    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
  • INSIDER21d
    SEC Form 4 filed by Harrigan Edmund
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022